Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 579

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Engaging neuroscience to advance translational research in brain barrier biology

Open access
Neuwelt, Edward A., Bauer, Björn, Fahlke, Christoph, Fricker, Gert, Iadecola, Constantino, Janigro, Damir, Leybaert, Luc, Molnár, Zoltán, O'Donnell, Martha E., Povlishock, John T., Saunders, Norman R., Sharp, Frank, Stanimirovic, Danica, Watts, Ryan J., Drewes, Lester R.·2011·Nature Reviews Neuroscience
DOI 10.1038/nrn2995
Open this paper in CoChat — free account

Abstract

The delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by brain barriers, of which the most well known are the blood–brain barrier (BBB) and the blood–cerebrospinal fluid (CSF) barrier. Recent studies have shown numerous additional roles of these barriers, including an involvement in neurodevelopment, in the control of cerebral blood flow, and — when barrier integrity is impaired — in the pathology of many common CNS disorders such as Alzheimer's disease, Parkinson's disease and stroke.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrn2995

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 190

  1. Selkoe, D. J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627–638 (2004). · DOI · Paper page
  2. Zlokovic, B. V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202–208 (2005). · DOI · Paper page
  3. Kortekaas, R. et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176–179 (2005). · DOI · Paper page
  4. Hemmer, B., Cepok, S., Zhou, D. & Sommer, N. Multiple sclerosis — a coordinated immune attack across the blood brain barrier. Curr. Neurovasc. Res. 1, 141–150 (2004). · DOI
  5. Barzo, P., Marmarou, A., Fatouros, P., Hayasaki, K. & Corwin, F. Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging. J. Neurosurg. 87, 900–907 (1997). · DOI · Paper page
  6. Jain, R. K. et al. Angiogenesis in brain tumours. Nature Rev. Neurosci. 8, 610–622 (2007). · DOI · Paper page
  7. Papadopoulos, M. C. et al. Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol. Appl. Neurobiol. 27, 384–395 (2001). · DOI
  8. Belayev, L., Busto, R., Zhao, W. & Ginsberg, M. D. Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739, 88–96 (1996). · DOI · Paper page
  9. Benchenane, K., Lopez-Atalaya, J. P., Fernandez-Monreal, M., Touzani, O. & Vivien, D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27, 155–160 (2004). · DOI
  10. Kuroiwa, T., Ting, P., Martinez, H. & Klatzo, I. The biphasic opening of the blood–brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol. 68, 122–129 (1985). · DOI · Paper page
  11. Navarro Mora, G. et al. Does pilocarpine-induced epilepsy in adult rats require status epilepticus? PLoS ONE 4, e5759 (2009). · DOI
  12. Takano, T. et al. Astrocyte-mediated control of cerebral blood flow. Nature Neurosci. 9, 260–267 (2006). · DOI · Paper page
  13. Iadecola, C. & Nedergaard, M. Glial regulation of the cerebral microvasculature. Nature Neurosci. 10, 1369–1376 (2007). A comprehensive review of the role of astrocytes in the control of cerebral blood flow, highlighting some of the areas that require more research. · DOI · Paper page
  14. Neuwelt, E. et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 7, 84–96 (2008). · DOI · Paper page
  15. Grotta, J. C., Jacobs, T. P., Koroshetz, W. J. & Moskowitz, M. A. Stroke program review group: an interim report. Stroke 39, 1364–1370 (2008). · DOI
  16. Barres, B. A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430–440 (2008). A concise and complete primer on the role of astrocytes in brain function, with emphasis on their role in BBB function. · DOI · Paper page
  17. Leybaert, L. Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling? J. Cereb. Blood Flow Metab. 25, 2–16 (2005). · DOI
  18. Lok, J. et al. Cell–cell signalling in the neurovascular unit. Neurochem. Res. 32, 2032–2045 (2007). · DOI · Paper page
  19. Daneman, R. et al. Wnt/beta-catenin signalling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl Acad. Sci. USA 106, 641–646 (2009). · DOI · Paper page
  20. McCarty, J. H. Cell adhesion and signalling networks in brain neurovascular units. Curr. Opin. Hematol. 16, 209–214 (2009). · DOI
  21. MacAulay, N. & Zeuthen, T. Water transport between CNS compartments: contributions of aquaporins and cotransporters. Neuroscience 168, 941–956 (2010). · DOI
  22. Miller, D. S. Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends Pharmacol. Sci. 31, 246–254 (2010). A comprehensive, up-to-date survey of efflux transporters at the BBB, with a review of current knowledge of Pgp (the best studied efflux transporter) mechanisms. · DOI · Paper page
  23. Kimelberg, H. K. & Nedergaard, M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 7, 338–353 (2010). · DOI · Paper page
  24. Pedersen, S. F., O'Donnell, M. E., Anderson, S. E. & Cala, P. M. Physiology and pathophysiology of Na+/H+ exchange and Na+-K+-2Cl− cotransport in the heart, brain, and blood. Am. J. Physiol. Regul. Integr Comp. Physiol. 291, R1–R25 (2006). · DOI
  25. Jin, R., Yang, G. & Li, G. Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis. 38, 376–385 (2010). · DOI · Paper page
  26. Madri, J. A. Modeling the neurovascular niche: implications for recovery from CNS injury. J. Physiol. Pharmacol. 60 (Suppl. 4), 95–104 (2009).
  27. Ohtsuki, S. & Terasaki, T. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24, 1745–1758 (2007). · DOI · Paper page
  28. Enerson, B. E. & Drewes, L. R. The rat blood–brain barrier transcriptome. J. Cereb. Blood Flow Metab. 26, 959–973 (2006). · DOI · Paper page
  29. Pardridge, W. M. Molecular biology of the blood–brain barrier. Methods Mol. Med. 89, 385–399 (2003).
  30. Torres, G. E. & Amara, S. G. Glutamate and monoamine transporters: new visions of form and function. Curr. Opin. Neurobiol. 17, 304–312 (2007). · DOI
  31. Locher, K. P. Review. Structure and mechanism of ATP-binding cassette transporters. Phil. Trans. R. Soc. Lond. B 364, 239–245 (2009).
  32. Melzer, N., Torres-Salazar, D. & Fahlke, C. A dynamic switch between inhibitory and excitatory currents in a neuronal glutamate transporter. Proc. Natl Acad. Sci. USA 102, 19214–19218 (2005). · doi:10.1073/pnas.0508837103
  33. Bunch, L., Erichsen, M. N. & Jensen, A. A. Excitatory amino acid transporters as potential drug targets. Expert Opin. Ther. Targets. 13, 719–731 (2009). · DOI
  34. Bridges, R. J. & Esslinger, C. S. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol. Ther. 107, 271–285 (2005). · DOI
  35. Gonzalez, M. I. & Robinson, M. B. Neurotransmitter transporters: why dance with so many partners? Curr. Opin. Pharmacol. 4, 30–35 (2004). · DOI
  36. Chen, L. M., Haddad, G. G. & Boron, W. F. Effects of chronic continuous hypoxia on the expression of SLC4A8 (NDCBE) in neonatal versus adult mouse brain. Brain Res. 1238, 85–92 (2008). · DOI
  37. Bevensee, M. O. & Boron, W. F. Effects of acute hypoxia on intracellular-pH regulation in astrocytes cultured from rat hippocampus. Brain Res. 1193, 143–152 (2008). · doi:10.1016/j.brainres.2007.12.002
  38. Chen, L. M. et al. Expression and localization of Na-driven Cl–HCO3– exchanger (SLC4A8) in rodent CNS. Neuroscience 153, 162–174 (2008). · DOI
  39. Amiry-Moghaddam, M. et al. An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc. Natl Acad. Sci. USA 100, 2106–2111 (2003). · DOI · Paper page
  40. Benfenati, V. & Ferroni, S. Water transport between CNS compartments: functional and molecular interactions between aquaporins and ion channels. Neuroscience 168, 926–940 (2010). · DOI
  41. Speake, T., Freeman, L. J. & Brown, P. D. Expression of aquaporin 1 and aquaporin 4 water channels in rat choroid plexus. Biochim. Biophys. Acta 1609, 80–86 (2003). · DOI
  42. Gunnarson, E., Zelenina, M. & Aperia, A. Regulation of brain aquaporins. Neuroscience 129, 947–955 (2004). · DOI
  43. King, L. S., Kozono, D. & Agre, P. From structure to disease: the evolving tale of aquaporin biology. Nature Rev. Mol. Cell Biol. 5, 687–698 (2004). · DOI · Paper page
  44. Badaut, J., Lasbennes, F., Magistretti, P. J. & Regli, L. Aquaporins in brain: distribution, physiology, and pathophysiology. J. Cereb Blood Flow Metab. 22, 367–378 (2002). · DOI · Paper page
  45. Francesca, B. & Rezzani, R. Aquaporin and blood brain barrier. Curr. Neuropharmacol. 8, 92–96 (2010). · DOI
  46. Musa-Aziz, R., Chen, L. M., Pelletier, M. F. & Boron, W. F. Relative CO2/NH3 selectivities of AQP1, AQP4, AQP5, AmtB, and RhAG. Proc. Natl Acad. Sci. USA 106, 5406–5411 (2009). · DOI · Paper page
  47. Rigor, R. R., Hawkins, B. T. & Miller, D. S. Activation of PKC isoform beta(I) at the blood–brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J. Cereb Blood Flow Metab. 30, 1373–1383 (2010). · DOI
  48. Raffa, R. B. & Tallarida, R. J. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. J. Clin. Pharm. Ther. 35, 249–255 (2010). · doi:10.1111/j.1365-2710.2009.01086.x
  49. Hartz, A. M., Miller, D. S. & Bauer, B. Restoring blood–brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77, 715–723 (2010). · DOI · Paper page
  50. Loscher, W. & Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Rev. Neurosci. 6, 591–602 (2005). · DOI · Paper page
  51. Fletcher, J. I., Haber, M., Henderson, M. J. & Norris, M. D. ABC transporters in cancer: more than just drug efflux pumps. Nature Rev. Cancer 10, 147–156 (2010). · DOI · Paper page
  52. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv. Drug Deliv. Rev. 36, 179–194 (1999). · DOI · Paper page
  53. Hartz, A. M., Bauer, B., Fricker, G. & Miller, D. S. Rapid regulation of P-glycoprotein at the blood–brain barrier by endothelin-1. Mol. Pharmacol. 66, 387–394 (2004). · DOI
  54. Hartz, A. M., Bauer, B., Fricker, G. & Miller, D. S. Rapid modulation of P-glycoprotein-mediated transport at the blood–brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol. 69, 462–470 (2006). · DOI
  55. Bankstahl, J. P., Hoffmann, K., Bethmann, K. & Loscher, W. Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology 54, 1006–1016 (2008). · DOI
  56. Bauer, B. et al. Seizure-induced up-regulation of P-glycoprotein at the blood–brain barrier through glutamate and cyclooxygenase-2 signalling. Mol. Pharmacol. 73, 1444–1453 (2008). · DOI · Paper page
  57. Pekcec, A. et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 330, 939–947 (2009). · DOI
  58. Zibell, G. et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56, 849–855 (2009). · DOI
  59. Schlichtiger, J. et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br. J. Pharmacol. 160, 1062–1071 (2010). · DOI
  60. Bauer, B. et al. In vivo activation of human pregnane X receptor tightens the blood–brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70, 1212–1219 (2006). · DOI
  61. Wang, X., Sykes, D. B. & Miller, D. S. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. Mol. Pharmacol. 78, 376–383 (2010). · DOI
  62. Wang, X., Hawkins, B. T. & Miller, D. S. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. FASEB J. 25, 646–652 (2010).
  63. Bauer, B., Hartz, A. M., Fricker, G. & Miller, D. S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol. Pharmacol. 66, 413–419 (2004). · DOI · Paper page
  64. Dauchy, S. et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier. J. Neurochem. 107, 1518–1528 (2008). · DOI · Paper page
  65. Narang, V. S. et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood–brain barrier. Am. J. Physiol. Cell Physiol. 295, C440–450 (2008). · DOI
  66. Ott, M., Fricker, G. & Bauer, B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood–brain barrier: functional similarities between pig and human PXR. J. Pharmacol. Exp. Ther. 329, 141–149 (2009). · DOI
  67. Miller, D. S., Bauer, B. & Hartz, A. M. Modulation of P-glycoprotein at the blood–brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev. 60, 196–209 (2008). · DOI · Paper page
  68. Hartz, A. M. & Bauer, B. Regulation of ABC transporters at the blood–brain barrier: new targets for CNS therapy. Mol. Interv. 10, 293–304 (2010). · DOI
  69. Saitou, M. et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 11, 4131–4142 (2000). · DOI · Paper page
  70. Volterra, A. & Meldolesi, J. Astrocytes, from brain glue to communication elements: the revolution continues. Nature Rev. Neurosci. 6, 626–640 (2005). · DOI · Paper page
  71. Ding, S. et al. Enhanced astrocytic Ca2+ signals contribute to neuronal excitotoxicity after status epilepticus. J. Neurosci. 27, 10674–10684 (2007). · DOI · Paper page
  72. Takata, N. & Hirase, H. Cortical layer 1 and layer 2/3 astrocytes exhibit distinct calcium dynamics in vivo. PLoS ONE 3, e2525 (2008). · DOI
  73. Mulligan, S. J. & MacVicar, B. A. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431, 195–199 (2004). · DOI · Paper page
  74. Zonta, M. et al. Neuron-to-astrocyte signalling is central to the dynamic control of brain microcirculation. Nature Neurosci. 6, 43–50 (2003). · DOI · Paper page
  75. Koehler, R. C., Roman, R. J. & Harder, D. R. Astrocytes and the regulation of cerebral blood flow. Trends Neurosci. 30, 160–169 (2009). · DOI · Paper page
  76. Haydon, P. G. & Carmignoto, G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 86, 1009–1031 (2006). · DOI · Paper page
  77. Gordon, G. R., Choi, H. B., Rungta, R. L., Ellis-Davies, G. C. & MacVicar, B. A. Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745–749 (2008). · DOI · Paper page
  78. Tam, S. J. & Watts, R. J. Connecting vascular and nervous system development: angiogenesis and the blood–brain barrier. Annu. Rev. Neurosci. 33, 379–408 (2010). A comprehensive, up-to-date review of parallels in angiogenesis and development of BBB properties. · DOI · Paper page
  79. Stubbs, D. et al. Neurovascular congruence during cerebral cortical development. Cereb Cortex 19, (Suppl. 1) I32–I41 (2009). · DOI · Paper page
  80. Risau, W. & Wolburg, H. Development of the blood–brain barrier. Trends Neurosci. 13, 174–178 (1990). · DOI · Paper page
  81. Harrigan, M. R. Angiogenic factors in the central nervous system. Neurosurgery 53, 639–660 (2003). · DOI
  82. Risau, W. Mechanisms of angiogenesis. Nature 386, 671–674 (1997). · DOI · Paper page
  83. Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738–4747 (1995). · DOI · Paper page
  84. Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685–693 (2003). · DOI · Paper page
  85. Greenberg, D. A. & Jin, K. From angiogenesis to neuropathology. Nature 438, 954–959 (2005). · DOI · Paper page
  86. Dziegielewska, K. M. et al. Plasma proteins in fetal sheep brain: blood–brain barrier and intracerebral distribution. J. Physiol. 318, 239–250 (1981). · doi:10.1113/jphysiol.1981.sp013861
  87. Dziegielewska, K. M. et al. Studies of the development of brain barrier systems to lipid insoluble molecules in fetal sheep. J. Physiol. 292, 207–231 (1979). · DOI
  88. Evans, C. A., Reynolds, J. M., Reynolds, M. L., Saunders, N. R. & Segal, M. B. The development of a blood–brain barrier mechanism in foetal sheep. J. Physiol. 238, 371–386 (1974). · DOI
  89. Mollgard, K. & Saunders, N. R. The development of the human blood–brain and blood–CSF barriers. Neuropathol. Appl. Neurobiol. 12, 337–358 (1986). · DOI
  90. Johansson, P. A., Dziegielewska, K. M., Liddelow, S. A. & Saunders, N. R. The blood–CSF barrier explained: when development is not immaturity. Bioessays 30, 237–248 (2008). · DOI
  91. Ek, C. J., Dziegielewska, K. M., Stolp, H. & Saunders, N. R. Functional effectiveness of the blood–brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). J. Comp. Neurol. 496, 13–26 (2006). · DOI
  92. Gazzin, S. et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood–brain interfaces. J. Comp. Neurol. 510, 497–507 (2008). · DOI
  93. Kalabis, G. M., Petropoulos, S., Gibb, W. & Matthews, S. G. Breast cancer resistance protein (Bcrp1/Abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone. Placenta 28, 1073–1081 (2007). · DOI
  94. Ek, C. J. et al. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol. Lett. 197, 51–59 (2010). · DOI
  95. Daneman, R. et al. The mouse blood–brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS ONE 5, e13741 (2010). A large-scale screen of gene expression in adult and postnatal cerebral endothelial cells compared with liver and lung endothelial cells. · DOI · Paper page
  96. Wosik, K. et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 27, 9032–9042 (2007). · DOI · Paper page
  97. Liddelow, S. A. et al. Cellular transfer of macromolecules across the developing choroid plexus of Monodelphis domestica. Eur. J. Neurosci. 29, 253–266 (2009). · DOI
  98. Liddelow, S. A. et al. Modification of protein transfer across blood/cerebrospinal fluid barrier in response to altered plasma protein composition during development. Eur. J. Neurosci. 33, 391–400 (2010). · doi:10.1111/j.1460-9568.2010.07509.x
  99. Krasney, J. A. A neurogenic basis for acute altitude illness. Med. Sci. Sports Exerc. 26, 195–208 (1994). · doi:10.1249/00005768-199402000-00010
  100. Severinghaus, J. W. Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. J. Appl. Physiol. 79, 375–379 (1995). · DOI
  101. Wilson, M. H., Newman, S. & Imray, C. H. The cerebral effects of ascent to high altitudes. Lancet Neurol. 8, 175–191 (2009). · DOI · Paper page
  102. Laursen, H. Cerebral vessels and glial cells in liver disease. A morphometric and electron microscopic investigation. Acta Neurol. Scand. 65, 381–412 (1982). · DOI
  103. Martinez, A. Electron microscopy in human hepatic encephalopathy. Acta Neuropathol. 11, 82–86 (1968). · DOI
  104. Tripathi, A. K., Sha, W., Shulaev, V., Stins, M. F. & Sullivan, D. J. Jr. Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood 114, 4243–4252 (2009). · DOI
  105. Tripathi, A. K., Sullivan, D. J. & Stins, M. F. Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-kappaB. Infect. Immun. 74, 3262–3270 (2006). · DOI
  106. Tripathi, A. K., Sullivan, D. J. & Stins, M. F. Plasmodium falciparum-infected erythrocytes decrease the integrity of human blood–brain barrier endothelial cell monolayers. J. Infect. Dis. 195, 942–950 (2007). · DOI
  107. Engelhardt, B. & Kappos, L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 5, 16–22 (2008). · DOI
  108. Spencer, B. J. & Verma, I. M. Targeted delivery of proteins across the blood–brain barrier. Proc. Natl Acad. Sci. USA 104, 7594–7599 (2007). · DOI
  109. Hoffman, A. S. The origins and evolution of 'controlled' drug delivery systems. J. Control Release 132, 153–163 (2008). · DOI · Paper page
  110. Pardridge, W. M. Biopharmaceutical drug targeting to the brain. J. Drug Target 18, 157–167 (2010). A review of methods for delivering large molecules to the brain. · DOI
  111. Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010). · DOI
  112. Farkas, E., De Jong, G. I., de Vos, R. A., Jansen Steur, E. N. & Luiten, P. G. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol. 100, 395–402 (2000). · DOI
  113. Levy, E. et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126 (1990). · DOI · Paper page
  114. Premkumar, D. R., Cohen, D. L., Hedera, P., Friedland, R. P. & Kalaria, R. N. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am. J. Pathol. 148, 2083–2095 (1996).
  115. Westerlund, M. et al. Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat Disord. 15, 422–424 (2009). · DOI
  116. Weber, Y. G. et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J. Clin. Invest. 118, 2157–2168 (2008). · DOI · Paper page
  117. Suls, A. et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 131, 1831–1844 (2008). · doi:10.1093/brain/awn113
  118. Newmeyer, A., Cecil, K. M., Schapiro, M., Clark, J. F. & Degrauw, T. J. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. J. Dev. Behav. Pediatr. 26, 276–282 (2005). · DOI
  119. Klepper, J. Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia 49 (Suppl. 8) 46–49 (2008). · DOI · Paper page
  120. Kim, W. S., Weickert, C. S. & Garner, B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 104, 1145–1166 (2008). · DOI · Paper page
  121. Drozdzik, M. et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13, 259–263 (2003). · DOI
  122. Dean, M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400, 409–429 (2005). · DOI · Paper page
  123. Blanz, J. et al. Leukoencephalopathy upon disruption of the chloride channel ClC-2. J. Neurosci. 27, 6581–6589 (2007). · DOI
  124. Fabene, P. F. et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nature Med. 14, 1377–1383 (2008). · DOI · Paper page
  125. Kreutzberg, G. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312–318 (1996). · DOI · Paper page
  126. Appel, S. H., Beers, D. R. & Henkel, J. S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 31, 7–17 (2010). · DOI · Paper page
  127. Freudiger, C. W. et al. Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science 322, 1857–1861 (2008). · DOI · Paper page
  128. Seeley, E. H. & Caprioli, R. M. Molecular imaging of proteins in tissues by mass spectrometry. Proc. Natl Acad. Sci. USA 105, 18126–18131 (2008). · DOI · Paper page
  129. Todman, M. G., Han, S. K. & Herbison, A. E. Profiling neurotransmitter receptor expression in mouse gonadotropin-releasing hormone neurons using green fluorescent protein-promoter transgenics and microarrays. Neuroscience 132, 703–712 (2005). · DOI
  130. Turney, S. G. & Lichtman, J. W. Imaging fluorescent mice in vivo using confocal microscopy. Methods Cell Biol. 89, 309–327 (2008). · doi:10.1016/s0091-679x(08)00611-0
  131. Zhuo, L. et al. Live astrocytes visualized by green fluorescent protein in transgenic mice. Dev. Biol. 187, 36–42 (1997). · DOI · Paper page
  132. Priller, J. et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nature Med. 7, 1356–1361 (2001). · DOI · Paper page
  133. Miesenbock, G. The optogenetic catechism. Science 326, 395–399 (2009). · DOI · Paper page
  134. Iqbal, U. et al. Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br. J. Cancer 103, 1606–1616 (2010). · DOI
  135. Elsinga, P. H., Hendrikse, N. H., Bart, J., van Waarde, A. & Vaalburg, W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging Biol. 7, 37–44 (2005). · DOI
  136. Muldoon, L. L. et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25, 2295–2305 (2007). This paper demonstrated the important finding that most chemotherapy crosses the blood–tumour barrier to some degree but not nearly as well as systemic tissues, even in highly malignant tumours. · DOI · Paper page
  137. Angelov, L. et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J. Clin. Oncol. 27, 3503–3509 (2009). · DOI · Paper page
  138. Eliceiri, B. P., Gonzalez, A. M. & Baird, A. Zebrafish model of the blood–brain barrier: morphological and permeability studies. Methods Mol. Biol. 686, 371–378 (2011). An important new model for in vivo BBB studies, especially in development. · DOI
  139. Hartz, A. M. & Bauer, B. ABC Transporters in the CNS — an inventory. Curr. Pharm. Biotechnol. 12, 423–440 (2011). · DOI
  140. Saunders, N. R., Ek, C. J., Habgood, M. D. & Dziegielewska, K. M. Barriers in the brain: a renaissance? Trends Neurosci. 31, 279–286 (2008). · DOI
  141. Bates, K. A. et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 16, 16 (2008).
  142. Vogelgesang, S. et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12, 535–541 (2002). · DOI · Paper page
  143. Xiong, H. et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood–brain barrier for Abeta(1–40) peptides. J. Neurosci. 29, 5463–5475 (2009). · DOI
  144. Lu, A. et al. Reperfusion activates metalloproteinases that contribute to neurovascular injury. Exp. Neurol. 210, 549–559 (2008). · DOI
  145. Wang, X., Rosell, A. & Lo, E. H. Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. CNS Neurol. Disord. Drug Targets. 7, 235–242 (2008). · DOI
  146. Xue, M. & Yong, V. W. Matrix metalloproteinases in intracerebral hemorrhage. Neurol. Res. 30, 775–782 (2008). · DOI
  147. Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A. & John, G. R. VEGF-mediated disruption of endothelial CLN-5 promotes blood–brain barrier breakdown. Proc. Natl Acad. Sci. USA. 106(6):1977–1982 (2009). · DOI · Paper page
  148. Guzeloglu-Kayisli, O. et al. KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery 54, 943–949; discussion 949 (2004). · DOI
  149. Pagenstecher, A., Stahl, S., Sure, U. & Felbor, U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum. Mol. Genet. 18, 911–918 (2009). · DOI
  150. Candelario-Jalil, E., Yang, Y. & Rosenberg, G. A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983–994 (2009). · DOI · Paper page
  151. Gidday, J. M. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood–brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289, H558–H568 (2005). · DOI · Paper page
  152. Strbian, D. et al. The blood–brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 153, 175–181 (2008). · DOI · Paper page
  153. Simard, J. M. et al. Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke. Nature Med. 12, 433–440 (2006). · DOI · Paper page
  154. Hughes, J. R. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol. Res. 30, 920–925 (2008). · doi:10.1179/174313208x319116
  155. Mignot, C. et al. Alexander disease: putative mechanisms of an astrocytic encephalopathy. Cell. Mol. Life Sci. 61, 369–385 (2004). · DOI
  156. Chaudhuri, A., Yang, B., Gendelman, H. E., Persidsky, Y. & Kanmogne, G. D. STAT1 signalling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood–brain barrier. Blood 111, 2062–2072 (2008). · DOI
  157. Huang, W., Eum, S. Y., Andras, I. E., Hennig, B. & Toborek, M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J. 23, 1596–1606 (2009). · DOI
  158. de Lagerie, S. B. et al. MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA. J. Parasitol. 94, 1139–1142 (2008). · doi:10.1645/ge-1493.1
  159. Unkmeir, A. et al. Fibronectin mediates Opc-dependent internalization of Neisseria meningitidis in human brain microvascular endothelial cells. Mol. Microbiol 46, 933–946 (2002). · DOI
  160. Wang, L. & Lin, M. A novel cell wall-anchored peptidoglycan hydrolase (autolysin), IspC, essential for Listeria monocytogenes virulence: genetic and proteomic analysis. Microbiology 154, 1900–1913 (2008). · DOI
  161. Banks, W. A. Physiology and pathology of the blood–brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol. 5, 538–555 (1999). · DOI
  162. Haorah, J. et al. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood–brain barrier dysfunction. J. Neurochem. 101, 566–576 (2007). · DOI · Paper page
  163. Man, S., Ubogu, E. E. & Ransohoff, R. M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 17, 243–250 (2007). · DOI
  164. Suidan, G. L., McDole, J. R., Chen, Y., Pirko, I. & Johnson, A. J. Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS ONE 3, e3037 (2008). · DOI
  165. Verkman, A. S. Mammalian aquaporins: diverse physiological roles and potential clinical significance. Expert Rev. Mol. Med. 10, e13 (2008). · DOI
  166. Yang, B., Zador, Z. & Verkman, A. S. Glial cell aquaporin-4 overexpression in transgenic mice accelerates cytotoxic brain swelling. J. Biol. Chem. 283, 15280–15286 (2008). · DOI
  167. Blecharz, K. G., Drenckhahn, D. & Forster, C. Y. Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J. Cereb Blood Flow Metab. 28, 1139–1149 (2008). · DOI
  168. Felinski, E. A., Cox, A. E., Phillips, B. E. & Antonetti, D. A. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp. Eye Res. 86, 867–878 (2008). · DOI
  169. Harke, N., Leers, J., Kietz, S., Drenckhahn, D. & Forster, C. Glucocorticoids regulate the human occludin gene through a single imperfect palindromic glucocorticoid response element. Mol. Cell Endocrinol. 295, 39–47 (2008). · DOI
  170. Reijerkerk, A. et al. Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier. J. Immunol. 181, 3567–3574 (2008). · DOI
  171. Goodin, D. S., Cohen, B. A., O'Connor, P., Kappos, L. & Stevens, J. C. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71, 766–773 (2008). · DOI
  172. Lutterotti, A. & Martin, R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7, 538–547 (2008). · DOI
  173. Martin, C. et al. FGF2 plays a key role in embryonic cerebrospinal fluid trophic properties over chick embryo neuroepithelial stem cells. Dev. Biol. 297, 402–416 (2006). · DOI
  174. Brooks, T. A. et al. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Res. 1120, 172–182 (2006). · DOI
  175. Foroutan, S., Brillault, J., Forbush, B. & O'Donnell, M. E. Moderate-to-severe ischemic conditions increase activity and phosphorylation of the cerebral microvascular endothelial cell Na+-K+-Cl− cotransporter. Am. J. Physiol. Cell Physiol. 289, C1492–C1501 (2005). · DOI · Paper page
  176. Lam, T. I., Anderson, S. E., Glaser, N. & O'Donnell, M. E. Bumetanide reduces cerebral edema formation in rats with diabetic ketoacidosis. Diabetes 54, 510–516 (2005). · DOI
  177. Lam, T. I. & O'Donnell, M. E. BBB Na/H exchange: plasma membrane distribution of NHE1 and NHE2 isoforms and stimulation by arginine vasopressin. FASEB J. 22, 734.3 (2008). · doi:10.1096/fasebj.22.1_supplement.734.3
  178. O'Donnell, M. E., Duong, V., Suvatne, J., Foroutan, S. & Johnson, D. M. Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent. Am. J. Physiol. Cell Physiol. 289, C283–292 (2005). · DOI
  179. O'Donnell, M. E., Lam, T. I., Tran, L. & Anderson, S. E. The role of the blood–brain barrier Na-K-2Cl cotransporter in stroke. Adv. Exp. Med. Biol. 559, 67–75 (2004). · DOI
  180. Yuen, N., Anderson, S. E., Glaser, N., Tancredi, D. J. & O'Donnell, M. E. Cerebral blood flow and cerebral edema in rats with diabetic ketoacidosis. Diabetes 57, 2588–2594 (2008). · DOI
  181. Banks, W. A. The blood–brain barrier as a cause of obesity. Curr. Pharm. Des. 14, 1606–1614 (2008). · DOI
  182. Jequier, E. Leptin signalling, adiposity, and energy balance. Ann. NY Acad. Sci. 967, 379–388 (2002). · DOI · Paper page
  183. Pan, W. et al. Astrocyte leptin receptor (ObR) and leptin transport in adult-onset obese mice. Endocrinology 149, 2798–2806 (2008). · DOI
  184. Luder, A. S., Tanner, S. M., de la Chapelle, A. & Walter, J. H. Amnionless (AMN) mutations in Imerslund-Grasbeck syndrome may be associated with disturbed vitamin B(12) transport into the CNS. J. Inherit Metab. Dis. 7, 7 (2008).
  185. Gordon, N. Canavan disease: a review of recent developments. Eur. J. Paediatr. Neurol. 5, 65–69 (2001). · DOI
  186. Urayama, A., Grubb, J. H., Sly, W. S. & Banks, W. A. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood–brain barrier. Proc. Natl Acad. Sci. USA 101, 12658–12663 (2004). · DOI · Paper page
  187. Uhr, M. et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57, 203–209 (2008). · DOI · Paper page
  188. Tanigami, H. et al. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats. Neuroscience 131, 437–449 (2005). · DOI
  189. Sugimoto, H., Koehler, R. C., Wilson, D. A., Brusilow, S. W. & Traystman, R. J. Methionine sulfoximine, a glutamine synthetase inhibitor, attenuates increased extracellular potassium activity during acute hyperammonemia. J. Cereb Blood Flow Metab. 17, 44–49 (1997). · DOI
  190. Strauss, G. I., Knudsen, G. M., Kondrup, J., Moller, K. & Larsen, F. S. Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology 121, 1109–1119 (2001). · DOI

Cited by

See all 579

Metadata

Authors
Neuwelt, E. A., Bauer, B., Fahlke, C., Fricker, G., Iadecola, C., Janigro, D., Leybaert, L., Molnár, Z., O'Donnell, M. E., Povlishock, J. T., Saunders, N. R., Sharp, F., Stanimirovic, D., Watts, R. J., & Drewes, L. R.
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2011-02-18
Volume
12
Issue
3
Pages
169-182
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
DOI
10.1038/nrn2995
OpenAlex
W2080938528
Cited by
579
References
27
FWCI
3.35
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.